Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review
Cancers · 26.06.2024 · 16 (13) · 2338
DOI: 10.3390/cancers16132338 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.06.2024. Verfasst von Juan Carlos Restrepo und 4 weiteren Autor:innen. Beteiligte Einrichtung: Grupo de Investigación en Salud Integral (GISI), Departamento Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Santiago de Cali, Dirección General de Investigaciones de la Universidad Santiago de Cali, Proyecto de fortalecimiento de grupo de investigación en salud integral.
Abstract (Originalsprache)
Non-small-cell lung cancer (NSCLC) comprises approximately 85% of all lung cancer cases, often diagnosed at advanced stages, which diminishes the effective treatment options and survival rates. This systematic review assesses the utility of emerging biomarkers—circulating tumor DNA (ctDNA), microRNAs (miRNAs), and the blood tumor mutational burden (bTMB)—enhanced by next-generation sequencing (NGS) to improve the diagnostic accuracy, prognostic evaluation, and treatment strategies in NSCLC. Analyzing data from 37 studies involving 10,332 patients from 2020 to 2024, the review highlights how biomarkers like ctDNA and PD-L1 expression critically inform the selection of personalized therapies, particularly beneficial in the advanced stages of NSCLC. These biomarkers are critical for prognostic assessments and in dynamically adapting treatment plans, where high PD-L1 expression and specific genetic mutations (e.g., ALK fusions, EGFR mutations) significantly guide the use of targeted therapies and immunotherapies. The findings recommend integrating these biomarkers into standardized clinical pathways to maximize their potential in enhancing the treatment precision, ultimately fostering significant advancements in oncology and improving patient outcomes and quality of life. This review substantiates the prognostic and predictive value of these biomarkers and emphasizes the need for ongoing innovation in biomarker research.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Grupo de Investigación en Salud Integral (GISI), Departamento Facultad de Salud, Universidad Santiago de Cali, Cali 760035, Colombia.
- Grupo de Investigación Unidad de Toxicidad In Vitro-UTi, Facultad de Ciencias, Universidad CES, Medellin 050021, Colombia.
- Specialization in Internal Medicine, Department of Health, Universidad Santiago de Cali, Cali 760035, Colombia.
ORCID-Profile: Juan Carlos Restrepo, Andrés Pareja López, Yamil Liscano
Förderung
- Universidad Santiago de Cali
- Dirección General de Investigaciones de la Universidad Santiago de Cali
- Proyecto de fortalecimiento de grupo de investigación en salud integral
Zitieren
APA
Restrepo, J. C., Martínez Guevara, D., Pareja López, A., Montenegro Palacios, J. F., & Liscano, Y. (2024). Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review. Cancers, 16(13), 2338. https://doi.org/10.3390/cancers16132338
Vancouver
Restrepo JC, Martínez Guevara D, Pareja López A, Montenegro Palacios JF, Liscano Y. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review. Cancers. 2024;16(13):2338. doi:10.3390/cancers16132338
BibTeX
@article{Restrepo2024,
author = {Restrepo, Juan Carlos and Martínez Guevara, Darly and Pareja López, Andrés and Montenegro Palacios, John Fernando and Liscano, Yamil},
title = {Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review},
journal = {Cancers},
year = {2024},
volume = {16},
number = {13},
pages = {2338},
doi = {10.3390/cancers16132338}
}
EUVIMED